Down-regulated miR-26a promotes proliferation, migration, and invasionvianegative regulation of MTDH in esophageal squamous cell carcinoma.
Numerous studies have reported that the role played by miR-26a in cancer is controversial, but whether miR-26a regulates metadherin (MTDH) expression in esophageal squamous cell carcinoma (ESCC) is unclear. We performed this study to investigate the clinical relevance of miR-26a expression in ESCC. miR-26a was detected by using thein situhybridization method. To functionally analyze the role of miR-26a in ESCC cell linesin vitro, KYSE-450 and Eca109 cells were employed, whose endogenous miR-26a was artificially down- or up-regulated, respectively, by using lentiviral-based transfection. There was significant association between miR-26a expression and clinical stage (P= 0.049), lymph node metastasis (P= 0.023), tumor volume (P= 0.003), and poor overall prognosis (P= 0.026). miR-26a was able to suppress proliferation and migration of ESCC cellsin vitroMoreover, we have confirmed that miR-26a can negatively regulate MTDH in ESCC cells by using luciferase reporter assay. In addition, to investigate the role miR-26a plays in cell proliferation, we nude mice were xenografted with ESCC cells whose miR-26a was stably down- and up-regulated. Together, our results show that miR-26a is capable of suppressing the proliferation and migration of ESCC cellsvianegative regulation of MTDH. Moreover, miR-26a expression was clinically relevant in cancer progression and poor prognosis, which supports the idea that miR-26a acts as a tumor suppressor in ESCC.-Yang, C., Zheng, S., Liu, T., Liu, Q., Dai, F., Zhou, J., Chen, Y., Sheyhidin, I., Lu, X. Down-regulated miR-26a promotes proliferation, migration, and invasionvianegative regulation of MTDH in esophageal squamous cell carcinoma.
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Chenchen
C
Yang
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Shutao
S
Zheng
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Tao
T
Liu
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Qing
Q
Liu
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Fang
F
Dai
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jian
J
Zhou
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yumei
Y
Chen
State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Ilyar
I
Sheyhidin
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; luxiaomei88@163.com.|State Key Laboratory Incubation Base of Xinjiang Major Diseases Research, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Xiaomei
X
Lu
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000235:genetics*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics*; D015536:Down-Regulation; D004938:Esophageal Neoplasms / Q000235:genetics*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism*; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics*; D009361:Neoplasm Invasiveness / Q000235:genetics; D016601:RNA-Binding Proteins
D015815:Cell Adhesion Molecules; D008565:Membrane Proteins; D035683:MicroRNAs; D016601:RNA-Binding Proteins; C528163:MIRN26 microRNA, human; C483039:MTDH protein, human; C543693:Mirn26 microRNA, mouse; C483038:Mtdh protein, mouse
ESCC; malignant phenotype; regulatory mechanism